(AGNG) Aging Population - Overview
Etf: Biotechnology, Medical Devices, Pharmaceuticals, Senior Living, Healthcare
Dividends
| Dividend Yield | 0.92% |
| Yield on Cost 5y | 1.12% |
| Yield CAGR 5y | 10.85% |
| Payout Consistency | 89.4% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 12.0% |
| Relative Tail Risk | 2.68% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 7.52 |
| Character TTM | |
|---|---|
| Beta | 0.543 |
| Beta Downside | 0.531 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.48% |
| CAGR/Max DD | 0.89 |
Description: AGNG Aging Population January 05, 2026
The Global X Aging Population ETF (NASDAQ: AGNG) allocates over 80% of its assets to the Indxx Aging Population Thematic Index, which tracks exchange-listed companies in developed markets that profit from longer lifespans and a growing elderly demographic. Core exposure includes biotechnology, medical-device manufacturers, pharmaceutical firms, senior-living operators, and specialty health-care service providers.
Key drivers underpinning the theme are: (1) the global population aged 65+ is projected to rise from 9% in 2023 to roughly 12% by 2035, expanding the addressable market for age-related products; (2) health-care spending on aging services is growing at a compound annual rate of ~5% in the U.S., outpacing overall GDP growth; and (3) biotech R&D intensity remains high, with the top 10 firms in the index collectively investing >$15 billion in pipeline development in 2023, supporting future revenue streams.
For a data-driven deep-dive into AGNG’s holdings, risk profile, and valuation metrics, you may find the analytics on ValueRay worth exploring.
What is the price of AGNG shares?
Over the past week, the price has changed by +1.72%, over one month by +2.08%, over three months by +11.23% and over the past year by +18.62%.
Is AGNG a buy, sell or hold?
What are the forecasts/targets for the AGNG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 41.7 | 11.1% |
AGNG Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 84.3m USD (84.3m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 84.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 84.3m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.91% (E(84.3m)/V(84.3m) * Re(7.91%) + (debt-free company))
Discount Rate = 7.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)